US4873192A
(en)
|
1987-02-17 |
1989-10-10 |
The United States Of America As Represented By The Department Of Health And Human Services |
Process for site specific mutagenesis without phenotypic selection
|
ATE199158T1
(en)
|
1991-12-23 |
2001-02-15 |
Bayer Ag |
HBV AMPLIFICATION PROBE FOR USE IN SOLUTION STAGE HYBRIDIZATION SANDWICH ASSAY
|
EP1288296A3
(en)
*
|
1992-05-11 |
2003-03-12 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for inhibiting HBV viral replication
|
US6015832A
(en)
|
1997-12-31 |
2000-01-18 |
The Regents Of The University Of Michigan |
Methods of inactivating bacteria including bacterial spores
|
US6506803B1
(en)
|
1999-04-28 |
2003-01-14 |
Regents Of The University Of Michigan |
Methods of preventing and treating microbial infections
|
US6559189B2
(en)
|
1999-04-28 |
2003-05-06 |
Regents Of The University Of Michigan |
Non-toxic antimicrobial compositions and methods of use
|
US6635676B2
(en)
|
1999-04-28 |
2003-10-21 |
Regents Of The University Of Michigan |
Non-toxic antimicrobial compositions and methods of use
|
US7767216B2
(en)
|
1999-04-28 |
2010-08-03 |
The Regents Of The University Of Michigan |
Antimicrobial compositions and methods of use
|
US6555674B2
(en)
|
2000-08-09 |
2003-04-29 |
Nsgene A/S |
JeT promoter
|
CN1204248C
(en)
*
|
2002-02-05 |
2005-06-01 |
中国人民解放军第四军医大学 |
Process for preparing target ribonuclease for curing hepatitis B virus infection
|
US7074596B2
(en)
|
2002-03-25 |
2006-07-11 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Synthesis and use of anti-reverse mRNA cap analogues
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
TW201402124A
(en)
|
2005-08-19 |
2014-01-16 |
Array Biopharma Inc |
8-substituted benzoazepines as toll-like receptor modulators
|
TWI382019B
(en)
|
2005-08-19 |
2013-01-11 |
Array Biopharma Inc |
Aminodiazepines as toll-like receptor modulators
|
EP4332227A1
(en)
|
2005-08-23 |
2024-03-06 |
The Trustees of the University of Pennsylvania |
Rna containing modified nucleosides and methods of use thereof
|
EP2484758B1
(en)
|
2005-10-18 |
2013-10-02 |
Precision Biosciences |
Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
|
JP4235837B2
(en)
|
2006-04-04 |
2009-03-11 |
セイコーエプソン株式会社 |
Graininess prediction, profile creation and printing device
|
US8338593B2
(en)
|
2006-07-07 |
2012-12-25 |
Gilead Sciences, Inc. |
Modulators of toll-like receptor 7
|
WO2009001159A1
(en)
|
2007-06-25 |
2008-12-31 |
Cellectis |
Method for enhancing the cleavage activity of i-crei derived meganucleases
|
US8748373B2
(en)
*
|
2007-02-21 |
2014-06-10 |
Fox Chase Cancer Center |
Hepatitis B virus compositions and methods of use
|
EA024359B1
(en)
|
2007-06-29 |
2016-09-30 |
Джилид Сайэнс, Инк. |
Purine derivatives and their use as modulators of toll-like receptor 7
|
EP3098309B1
(en)
*
|
2007-10-31 |
2019-04-10 |
Precision Biosciences, Inc. |
Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
|
WO2009086558A1
(en)
|
2008-01-02 |
2009-07-09 |
Tekmira Pharmaceuticals Corporation |
Improved compositions and methods for the delivery of nucleic acids
|
BRPI0915692B8
(en)
|
2008-07-08 |
2021-05-25 |
Incyte Corp |
compounds derived from 1,2,5-oxadiazoles, their solid form, their composition, as well as their uses
|
DK2313111T3
(en)
|
2008-08-01 |
2013-12-02 |
Ventirx Pharmaceuticals Inc |
Toll-like receptor agonist formulations and their use
|
AU2009333559B2
(en)
|
2008-12-09 |
2015-03-12 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
WO2010136981A2
(en)
|
2009-05-26 |
2010-12-02 |
Cellectis |
Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof
|
WO2010136841A2
(en)
*
|
2009-05-26 |
2010-12-02 |
Cellectis |
Meganuclease variants cleaving the genome of a non-genomically integrating virus and uses thereof
|
US8691809B2
(en)
|
2009-08-18 |
2014-04-08 |
Ventirx Pharmaceuticals, Inc. |
Substituted benzoazepines as toll-like receptor modulators
|
RU2580320C2
(en)
|
2009-08-18 |
2016-04-10 |
Вентиркс Фармасьютикалз, Инк. |
Substituted benzoazepines as toll-like receptor modulators
|
EP2491035B1
(en)
|
2009-10-22 |
2017-08-30 |
Gilead Sciences, Inc. |
Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections
|
US9186337B2
(en)
|
2010-02-24 |
2015-11-17 |
Oryzon Genomics S.A. |
Lysine demethylase inhibitors for diseases and disorders associated with Hepadnaviridae
|
PL2578585T3
(en)
|
2010-05-31 |
2017-01-31 |
Ono Pharmaceutical Co., Ltd. |
Purinone derivative as btk kinase inhibitor
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
ES2616449T3
(en)
|
2010-10-01 |
2017-06-13 |
Ventirx Pharmaceuticals, Inc. |
Therapeutic use of a TLR agonist and combination therapy
|
US20120082658A1
(en)
|
2010-10-01 |
2012-04-05 |
Ventirx Pharmaceuticals, Inc. |
Methods for the Treatment of Allergic Diseases
|
UY33775A
(en)
|
2010-12-10 |
2012-07-31 |
Gilead Sciences Inc |
MACROCYCLIC INHIBITORS OF VIRUS FLAVIVIRIDAE, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND THEIR USES
|
CN106749023A
(en)
|
2011-01-12 |
2017-05-31 |
帆德制药股份有限公司 |
As the substituted benzazepine of toll-like receptor conditioning agent
|
US20140088085A1
(en)
|
2011-01-12 |
2014-03-27 |
Array Biopharma, Inc |
Substituted Benzoazepines As Toll-Like Receptor Modulators
|
AP2013007110A0
(en)
|
2011-02-12 |
2013-09-30 |
Globeimmune Inc |
Yeast-based therapeutic for chronic hepatitis B infection
|
BR122017025423B1
(en)
|
2011-04-08 |
2021-05-11 |
Janssen Sciences Ireland Uc |
pyrimidine derivatives, their use in the treatment of viral infections and pharmaceutical composition comprising them
|
US8916575B2
(en)
|
2011-05-18 |
2014-12-23 |
Janssen R&D Ireland |
Quinazoline derivatives for the treatment of viral infections and further diseases
|
EP3683319A1
(en)
|
2011-06-01 |
2020-07-22 |
Precision Biosciences, Inc. |
Methods and products for producing engineered mammalian cell lines with amplified transgenes
|
EP2717895A1
(en)
|
2011-06-08 |
2014-04-16 |
Aurigene Discovery Technologies Limited |
Therapeutic compounds for immunomodulation
|
MX342731B
(en)
*
|
2011-06-30 |
2016-10-11 |
Arrowhead Res Corp |
Compositions and methods for inhibiting gene expression of hepatitis b virus.
|
WO2013006841A1
(en)
*
|
2011-07-06 |
2013-01-10 |
Yale University |
Stimulation of arterial collateral growth and lymphogenesis
|
BR112014012727B1
(en)
|
2011-11-29 |
2022-10-25 |
Ono Pharmaceutical Co., Ltd |
6-AMINO-9-[(3R)-1-(2-BUTINOYL)-3-PYRROLIDINYL]-7-(4-PHENOXYPHENYL)-7,9-DIHYDRO-8H-PURI-8-ONE E PHARMACEUTICAL COMPOSITION
|
SG10201608528YA
(en)
|
2011-12-21 |
2016-12-29 |
Novira Therapeutics Inc |
Hepatitis b antiviral agents
|
EP2812331B1
(en)
|
2012-02-08 |
2019-01-02 |
Janssen Sciences Ireland Unlimited Company |
Piperidino-pyrimidine derivatives for the treatment of viral infections
|
WO2013132317A1
(en)
|
2012-03-07 |
2013-09-12 |
Aurigene Discovery Technologies Limited |
Peptidomimetic compounds as immunomodulators
|
AU2013239366A1
(en)
|
2012-03-29 |
2014-10-16 |
Aurigene Discovery Technologies Limited |
Immunomodulating cyclic compounds from the BC loop of human PD1
|
US20130267517A1
(en)
|
2012-03-31 |
2013-10-10 |
Hoffmann-La Roche Inc. |
Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
MX2014011749A
(en)
|
2012-03-31 |
2015-01-22 |
Hoffmann La Roche |
Novel 4-methyl-dihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection.
|
WO2013159109A1
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Modulation of hepatitis b virus (hbv) expression
|
CN104470949A
(en)
|
2012-05-15 |
2015-03-25 |
百时美施贵宝公司 |
Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
|
AR091279A1
(en)
|
2012-06-08 |
2015-01-21 |
Gilead Sciences Inc |
MACROCICLIC INHIBITORS OF VIRUS FLAVIVIRIDAE
|
IN2014MN02658A
(en)
|
2012-06-08 |
2015-08-21 |
Gilead Sciences Inc |
|
ES2624223T3
(en)
|
2012-06-08 |
2017-07-13 |
Gilead Sciences, Inc. |
Macrocyclic inhibitors of flaviviridae viruses
|
EA029266B1
(en)
|
2012-08-10 |
2018-02-28 |
Янссен Сайенсиз Айрлэнд Юси |
Alkylpyrimidine derivatives for the treatment of viral infections
|
SG11201501360TA
(en)
|
2012-08-28 |
2015-03-30 |
Janssen Sciences Ireland Uc |
Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
CR20200276A
(en)
|
2012-08-28 |
2021-01-27 |
Janssen Sciences Ireland Uc |
SULFAMOYLARYLAMIDES AND THEIR USE AS MEDICINES FOR THE TREATMENT OF HEPATITIS B (DIVISIONAL EXP. 2015-0059)
|
BR112015004113A2
(en)
|
2012-09-10 |
2017-07-04 |
Hoffmann La Roche |
6-Amino Acid Heteroaryl Dihydropyrimidines for the Treatment and Prophylaxis of Hepatitis B Virus Infection
|
ES2654143T3
(en)
|
2012-10-02 |
2018-02-12 |
Gilead Sciences, Inc. |
Histone Demethylase Inhibitors
|
JP6293765B2
(en)
|
2012-10-10 |
2018-03-14 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
Pyrrolo [3,2-D] pyrimidine derivatives for the treatment of viral infections and other diseases
|
BR112015011036B1
(en)
|
2012-11-16 |
2022-02-01 |
Janssen Sciences Ireland Uc |
Heterocyclic Substituted 2-Amino-quinazoline Derivatives, Pharmaceutical Composition
|
ES2834959T3
(en)
|
2012-12-06 |
2021-06-21 |
Celgene Quanticel Res Inc |
Histone demethylase inhibitors
|
EP2934145B1
(en)
|
2012-12-19 |
2017-11-15 |
Celgene Quanticel Research, Inc. |
Histone demethylase inhibitors
|
SG11201504946VA
(en)
|
2012-12-21 |
2015-07-30 |
Quanticel Pharmaceuticals Inc |
Histone demethylase inhibitors
|
EA035174B1
(en)
|
2013-02-21 |
2020-05-12 |
Янссен Сайенсиз Айрлэнд Юси |
2-aminopyrimidine derivatives as modulators of toll-like receptors tlr7 and/or tlr8
|
CN105263906B
(en)
|
2013-02-27 |
2018-11-23 |
吉利德科学公司 |
The inhibitor of histone demethylase
|
JP6466348B2
(en)
|
2013-02-28 |
2019-02-06 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
Sulfamoyl-arylamide and its use as a medicament for treating hepatitis B
|
CA2903473A1
(en)
|
2013-03-12 |
2014-10-09 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
US8993771B2
(en)
|
2013-03-12 |
2015-03-31 |
Novira Therapeutics, Inc. |
Hepatitis B antiviral agents
|
BR112015022545A2
(en)
|
2013-03-13 |
2017-07-18 |
Constellation Pharmaceuticals Inc |
pyrazole compounds and the uses thereof
|
CA2903081A1
(en)
|
2013-03-14 |
2014-09-25 |
Quanticel Pharmaceuticals, Inc. |
Histone demethylase inhibitors
|
HUE034906T2
(en)
|
2013-03-15 |
2018-03-28 |
Quanticel Pharmaceuticals Inc |
Histone demethylase inhibitors
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
CA2922302C
(en)
|
2013-04-03 |
2021-08-03 |
Janssen Sciences Ireland Uc |
N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
WO2014179760A1
(en)
|
2013-05-03 |
2014-11-06 |
The Regents Of The University Of California |
Cyclic di-nucleotide induction of type i interferon
|
BR112015028873A2
(en)
|
2013-05-17 |
2017-07-25 |
Hoffmann La Roche |
6-linked heteroaryl dihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
|
JO3603B1
(en)
|
2013-05-17 |
2020-07-05 |
Janssen Sciences Ireland Uc |
Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
CN105960400B
(en)
|
2013-05-17 |
2019-05-31 |
爱尔兰詹森科学公司 |
Sulfamoylthiophene amide derivatives and its purposes for being used to treat hepatitis B as drug
|
CA2935719C
(en)
|
2013-07-25 |
2021-11-02 |
Janssen Sciences Ireland Uc |
Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
JP6401788B2
(en)
|
2013-07-30 |
2018-10-10 |
ヤンセン・サイエンシズ・アイルランド・ユーシー |
Thieno [3,2-d] pyrimidine derivatives for viral infection treatment
|
EP3030322A2
(en)
|
2013-08-05 |
2016-06-15 |
Cambridge Enterprise Limited |
Inhibition of cxcr4 signaling in cancer immunotherapy
|
US10471139B2
(en)
|
2013-08-15 |
2019-11-12 |
The University Of Kansas |
Toll-like receptor agonists
|
AU2014315457B2
(en)
|
2013-09-04 |
2018-05-10 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
JP6474412B2
(en)
|
2013-09-06 |
2019-02-27 |
オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited |
Cyclic peptidomimetic compounds as immunomodulators
|
SG11201601679TA
(en)
|
2013-09-06 |
2016-04-28 |
Aurigene Discovery Tech Ltd |
1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives as immunomodulators
|
ES2788848T3
(en)
|
2013-09-06 |
2020-10-23 |
Aurigene Discovery Tech Ltd |
1,2,4-Oxadiazole derivatives as immunomodulators
|
WO2015036927A1
(en)
|
2013-09-10 |
2015-03-19 |
Aurigene Discovery Technologies Limited |
Immunomodulating peptidomimetic derivatives
|
AU2014320463B2
(en)
|
2013-09-11 |
2018-08-02 |
Centre National De La Recherche Scientifique (Cnrs) |
Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection
|
WO2015044900A1
(en)
|
2013-09-27 |
2015-04-02 |
Aurigene Discovery Technologies Limited |
Therapeutic immunomodulating compounds
|
JP6483666B2
(en)
|
2013-10-14 |
2019-03-13 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Selectively substituted quinoline compounds
|
SI3057964T1
(en)
|
2013-10-14 |
2020-03-31 |
Eisai R&D Management Co., Ltd. |
Selectively substituted quinoline compounds
|
AP2016009122A0
(en)
|
2013-10-23 |
2016-03-31 |
Janssen Sciences Ireland Uc |
Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
WO2015073774A1
(en)
|
2013-11-14 |
2015-05-21 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis b infections
|
KR20160089530A
(en)
*
|
2013-12-12 |
2016-07-27 |
더 브로드 인스티튜트, 인코퍼레이티드 |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for hbv and viral diseases and disorders
|
CA2933466A1
(en)
|
2013-12-13 |
2015-06-18 |
Takeda Pharmaceutical Company Limited |
Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
|
US10654807B2
(en)
|
2013-12-20 |
2020-05-19 |
The University Of Kansas |
Toll-like receptor 8 agonists
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
US9181288B2
(en)
|
2014-01-16 |
2015-11-10 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
SG11201605970QA
(en)
|
2014-01-30 |
2016-08-30 |
Hoffmann La Roche |
Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
|
AU2015214404B2
(en)
|
2014-02-04 |
2020-10-01 |
Incyte Corporation |
Combination of a PD-1 antagonist and an IDO1 inhibitor for treating cancer
|
PL3102572T3
(en)
|
2014-02-06 |
2019-04-30 |
Janssen Sciences Ireland Uc |
Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
JP2017507155A
(en)
|
2014-03-05 |
2017-03-16 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Treatment of renal cancer using a combination of anti-PD-1 antibodies and other anticancer agents
|
PL3114128T3
(en)
|
2014-03-07 |
2019-06-28 |
F. Hoffmann-La Roche Ag |
Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
|
US9400280B2
(en)
|
2014-03-27 |
2016-07-26 |
Novira Therapeutics, Inc. |
Piperidine derivatives and methods of treating hepatitis B infections
|
US9850225B2
(en)
|
2014-04-14 |
2017-12-26 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
RS60430B1
(en)
|
2014-04-22 |
2020-07-31 |
Hoffmann La Roche |
4-amino-imidazoquinoline compounds
|
SG11201608299TA
(en)
|
2014-05-01 |
2016-11-29 |
Novartis Ag |
Compounds and compositions as toll-like receptor 7 agonists
|
WO2015168269A1
(en)
|
2014-05-01 |
2015-11-05 |
Novartis Ag |
Compounds and compositions as toll-like receptor 7 agonists
|
CA2948080A1
(en)
|
2014-05-13 |
2015-11-19 |
F. Hoffmann-La Roche Ag |
Novel dihydroquinolizinones for the treatment and prophylaxis of hepatitis b virus infection
|
JP6787792B2
(en)
|
2014-05-23 |
2020-11-18 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Combination treatment for the treatment of cancer
|
WO2015184268A1
(en)
|
2014-05-30 |
2015-12-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods of delivering treatments for latent viral infections
|
BR112016028255A2
(en)
|
2014-06-06 |
2017-08-22 |
Flexus Biosciences Inc |
immunoregulatory agents
|
WO2016012470A1
(en)
|
2014-07-25 |
2016-01-28 |
F. Hoffmann-La Roche Ag |
New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
|
SG10201900886RA
(en)
|
2014-08-01 |
2019-03-28 |
3M Innovative Properties Co |
Methods and therapeutic combinations for treating tumors
|
WO2016023877A1
(en)
|
2014-08-14 |
2016-02-18 |
F. Hoffmann-La Roche Ag |
Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection
|
SG11201701169XA
(en)
|
2014-08-15 |
2017-03-30 |
Chia Tai Tianqing Pharmaceutical Group Co Ltd |
Pyrrolopyrimidine compounds used as tlr7 agonist
|
US20170275287A1
(en)
|
2014-08-22 |
2017-09-28 |
Janus Biotherapeutics, Inc. |
Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
|
BR112017003442A2
(en)
|
2014-08-27 |
2017-11-28 |
Gilead Sciences Inc |
compounds and methods for inhibiting histone demethylases
|
US9884866B2
(en)
|
2014-09-08 |
2018-02-06 |
Regents Of The University Of Minnesota |
Immunomodulators and immunomodulator conjugates
|
TN2017000084A1
(en)
|
2014-09-11 |
2018-07-04 |
Bristol Myers Squibb Co |
Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
JP6783230B2
(en)
|
2014-10-10 |
2020-11-11 |
ジェネンテック, インコーポレイテッド |
Pyrrolidone amide compounds as inhibitors of histone demethylase
|
EP3204392A1
(en)
|
2014-10-11 |
2017-08-16 |
F. Hoffmann-La Roche AG |
Compounds for use in the treatment of infectious diseases
|
US9637485B2
(en)
|
2014-11-03 |
2017-05-02 |
Hoffmann-La Roche Inc. |
6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
|
UY36390A
(en)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
MODULATING COMPOUNDS OF INDOLAMINE ENZYME 2,3-DIOXYGENASE (IDO), ITS SYNTHESIS METHODS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
JP2017538678A
(en)
|
2014-11-05 |
2017-12-28 |
フレクサス・バイオサイエンシーズ・インコーポレイテッドFlexus Biosciences, Inc. |
Immunomodulator
|
BR112017009648A2
(en)
|
2014-11-13 |
2017-12-19 |
Glaxosmithkline Biologicals Sa |
compound, methods for treating allergic diseases or other inflammatory conditions or preventing disease, allergic rhinitis or asthma, composition, and use of a compound.
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
HUE053704T2
(en)
|
2014-12-08 |
2021-07-28 |
Hoffmann La Roche |
3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
JP6644792B2
(en)
|
2014-12-18 |
2020-02-12 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Benzazepine sulfonamide compound
|
US9944678B2
(en)
|
2014-12-19 |
2018-04-17 |
Bristol-Myers Squibb Company |
Immunomodulators
|
US9676793B2
(en)
|
2014-12-23 |
2017-06-13 |
Hoffmann-Laroche Inc. |
Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
|
AR103222A1
(en)
|
2014-12-23 |
2017-04-26 |
Hoffmann La Roche |
PROCEDURE FOR THE PREPARATION OF ANALOGS OF 4-PHENYL-5-ALCOXICARBONIL-2-THIAZOL-2-IL-1,4-DIHYDROPIRIMIDINE
|
CN105732635A
(en)
|
2014-12-29 |
2016-07-06 |
南京明德新药研发股份有限公司 |
Toll-like receptor 7 agonist
|
US9550779B2
(en)
|
2014-12-30 |
2017-01-24 |
Novira Therapeutics, Inc. |
Derivatives and methods of treating hepatitis B infections
|
WO2016107832A1
(en)
|
2014-12-30 |
2016-07-07 |
F. Hoffmann-La Roche Ag |
Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
|
EP3240913A1
(en)
|
2014-12-31 |
2017-11-08 |
F. Hoffmann-La Roche AG |
A novel high-throughput method for quantification of hbv cccdna from cell lysate by real-time pcr
|
MA41338B1
(en)
|
2015-01-16 |
2019-07-31 |
Hoffmann La Roche |
Pyrazine compounds for the treatment of infectious diseases
|
CN107208102B
(en)
|
2015-01-27 |
2021-07-06 |
豪夫迈·罗氏有限公司 |
Recombinant HBV CCcDNA, method for producing same and use thereof
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
EP3256471B1
(en)
|
2015-02-11 |
2018-12-12 |
F. Hoffmann-La Roche AG |
Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
CN107108615B
(en)
|
2015-03-04 |
2020-11-20 |
吉利德科学公司 |
Toll-like receptor modulating 4, 6-diamino-pyrido [3,2-D ] pyrimidine compounds
|
HUE042563T2
(en)
|
2015-03-06 |
2019-07-29 |
Hoffmann La Roche |
Benzazepine dicarboxamide compounds
|
WO2016142852A1
(en)
|
2015-03-10 |
2016-09-15 |
Aurigene Discovery Technologies Limited |
1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
|
BR112017019307A2
(en)
|
2015-03-10 |
2018-05-02 |
Aurigene Discovery Technologies Limited |
3-substituted 1,3,4-oxadiazole compounds and thiadiazole as immunomodulators
|
CA2979161A1
(en)
|
2015-03-10 |
2016-09-15 |
Aurigene Discovery Technologies Limited |
3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
EA034708B1
(en)
|
2015-03-10 |
2020-03-10 |
Ауриджен Дискавери Текнолоджис Лимитед |
1,2,4-oxadiazole and thiadiazole compounds as immunomodulators
|
AU2016230795A1
(en)
|
2015-03-10 |
2017-09-07 |
Aurigene Discovery Technologies Limited |
Therapeutic cyclic compounds as immunomodulators
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
WO2016161268A1
(en)
|
2015-04-01 |
2016-10-06 |
Enanta Pharmaceuticals, Inc. |
Hepatitis b antviral agents
|
CN107922377A
(en)
|
2015-04-17 |
2018-04-17 |
美国印第安纳大学研究和技术公司 |
Hepatitis B assembles effector
|
EP3292120B1
(en)
|
2015-05-04 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Tetrahydropyridopyrimidines and tetrahydropyridopyridines as inhibitors of hbsag (hbv surface antigen) and hbv dna production for the treatment of hepatitis b virus infections
|
EP3294746B1
(en)
|
2015-05-12 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Substituted aminothiazolopyrimidinedione derivatives for the treatment and prophylaxis of virus infection
|
US10196701B2
(en)
|
2015-06-01 |
2019-02-05 |
The Penn State Research Foundation |
Hepatitis B virus capsid assembly
|
GB201511477D0
(en)
|
2015-06-30 |
2015-08-12 |
Redx Pharma Plc |
Antiviral compounds
|
EP3317289B1
(en)
|
2015-06-30 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
WO2017007701A1
(en)
|
2015-07-07 |
2017-01-12 |
Merck Sharp & Dohme Corp. |
Antiviral phosphodiamide compounds
|
CN107849037B
(en)
|
2015-07-21 |
2020-04-17 |
豪夫迈·罗氏有限公司 |
Tricyclic 4-pyridone-3-carboxylic acid derivatives for the treatment and prevention of hepatitis B virus infection
|
WO2017016960A1
(en)
|
2015-07-24 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Process for the preparation of (6s)-6-alkyl-10-alkoxy-9-(substituted alkoxy)-2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid analogues
|
EP3328855B1
(en)
|
2015-07-27 |
2019-05-15 |
H. Hoffnabb-La Roche Ag |
Novel tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
|
WO2017017043A1
(en)
|
2015-07-28 |
2017-02-02 |
F. Hoffmann-La Roche Ag |
Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
|
US20180177872A1
(en)
|
2015-07-29 |
2018-06-28 |
Yong Jia |
Combination of PD-1 antagonist with an EGFR inhibitor
|
TWI639598B
(en)
|
2015-08-10 |
2018-11-01 |
美商默沙東藥廠 |
Antiviral beta-amino acid ester phosphodiamide compounds
|
AU2016304899B2
(en)
|
2015-08-13 |
2018-11-08 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
US11130736B2
(en)
|
2015-08-21 |
2021-09-28 |
University Of Kansas |
Human TLR8-selective agonists
|
WO2017038909A1
(en)
|
2015-08-28 |
2017-03-09 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compounds
|
WO2017040233A1
(en)
|
2015-08-31 |
2017-03-09 |
3M Innovative Properties Company |
GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS
|
TW201720802A
(en)
|
2015-09-15 |
2017-06-16 |
艾森伯利生物科學公司 |
Hepatitis B core protein modulators
|
WO2017047769A1
(en)
|
2015-09-17 |
2017-03-23 |
国立大学法人富山大学 |
Activation inhibitor for toll-like receptor 7 or toll-like receptor 9
|
WO2017046112A1
(en)
|
2015-09-17 |
2017-03-23 |
F. Hoffmann-La Roche Ag |
Sulfinylphenyl or sulfonimidoylphenyl benzazepines
|
JP6723254B2
(en)
|
2015-10-05 |
2020-07-15 |
富士フイルム富山化学株式会社 |
Anti-hepatitis B virus agent
|
CN108290845B
(en)
|
2015-10-07 |
2021-08-03 |
大日本住友制药株式会社 |
Pyrimidine compounds
|
US10745382B2
(en)
|
2015-10-15 |
2020-08-18 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
US20170107216A1
(en)
|
2015-10-19 |
2017-04-20 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
BR112018008339A2
(en)
|
2015-10-28 |
2018-10-30 |
Aduro Biotech Inc |
compositions and methods for activating interferon gene-dependent signaling enhancer
|
FI3371316T3
(en)
|
2015-11-04 |
2023-01-13 |
|
Vaccines against hepatitis b virus
|
CN108472245A
(en)
|
2015-11-04 |
2018-08-31 |
因赛特公司 |
For indole amine 2,3-dioxygenase inhibition and its pharmaceutical composition and method of indication
|
AU2016349080B2
(en)
|
2015-11-05 |
2019-03-14 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
7-(thiazol-5-yl) pyrrolopyrimidine compound as TLR7 agonist
|
AU2016358100B2
(en)
|
2015-11-19 |
2021-05-27 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
WO2017087678A2
(en)
|
2015-11-19 |
2017-05-26 |
Bristol-Myers Squibb Company |
Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
|
AU2016362697B2
(en)
|
2015-12-03 |
2018-07-12 |
Glaxosmithkline Intellectual Property Development Limited |
Cyclic purine dinucleotides as modulators of STING
|
US10745428B2
(en)
|
2015-12-10 |
2020-08-18 |
Idenix Pharmaceuticals Llc |
Antiviral phosphodiamide prodrugs of tenofovir
|
WO2017106740A1
(en)
|
2015-12-16 |
2017-06-22 |
Aduro Biotech, Inc. |
Methods for identifying inhibitors of "stimulator of interferon gene"-dependent interferon production
|
EP3889145B1
(en)
|
2015-12-17 |
2024-02-21 |
Merck Patent GmbH |
8-cyano-5-piperidino-quinolines as tlr7/8 antagonists and their uses for treating immune disorders
|
WO2017106634A1
(en)
|
2015-12-17 |
2017-06-22 |
Incyte Corporation |
N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators
|
DK3394033T3
(en)
|
2015-12-22 |
2021-01-04 |
Incyte Corp |
HETEROCYCLIC COMPOUNDS AS IMMUNE MODULATORS
|
EP3394253B1
(en)
*
|
2015-12-23 |
2021-09-01 |
Precision Biosciences, Inc. |
Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
|
CA3014369A1
(en)
|
2016-02-19 |
2017-08-24 |
Novartis Ag |
Tetracyclic pyridone compounds as antivirals
|
NZ746112A
(en)
|
2016-03-18 |
2023-01-27 |
Immune Sensor Llc |
Cyclic di-nucleotide compounds and methods of use
|
CA3018537A1
(en)
|
2016-03-21 |
2017-09-28 |
Council Of Scientific & Industrial Research |
Blocking toll-like receptor 9 signaling with small molecule antagonist
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
WO2017184735A1
(en)
|
2016-04-19 |
2017-10-26 |
Ifm Therapeutics, Inc |
Nlrp3 modulators
|
EP3445761A1
(en)
|
2016-04-19 |
2019-02-27 |
Innate Tumor Immunity, Inc. |
Nlrp3 modulators
|
WO2017186711A1
(en)
|
2016-04-25 |
2017-11-02 |
Invivogen |
Novel complexes of immunostimulatory compounds, and uses thereof
|
US11278632B2
(en)
|
2016-05-03 |
2022-03-22 |
Precision Biosciences, Inc. |
Engineered nucleases useful for treatment of hemophilia A
|
MA44860A
(en)
|
2016-05-06 |
2019-03-13 |
Incyte Holdings Corp |
HETEROCYCLIC COMPOUNDS USED AS IMMUNOMODULATORS
|
PL3453707T3
(en)
|
2016-05-06 |
2022-06-13 |
Shanghai De Novo Pharmatech Co., Ltd. |
Benzazepine derivative, preparation method, pharmaceutical composition and use thereof
|
EP3458455B1
(en)
|
2016-05-20 |
2021-06-16 |
F. Hoffmann-La Roche AG |
Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases
|
WO2017202703A1
(en)
|
2016-05-23 |
2017-11-30 |
F. Hoffmann-La Roche Ag |
Benzazepine dicarboxamide compounds with secondary amide function
|
EP3464245B1
(en)
|
2016-05-23 |
2020-10-14 |
H. Hoffnabb-La Roche Ag |
Benzazepine dicarboxamide compounds with tertiary amide function
|
US20170342060A1
(en)
|
2016-05-26 |
2017-11-30 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
EP3464278B1
(en)
|
2016-05-26 |
2021-06-16 |
F. Hoffmann-La Roche AG |
Xanthone derivatives for the treatment and prophylaxis of hepatitis b virus disease
|
WO2017211791A1
(en)
|
2016-06-07 |
2017-12-14 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbsag inhibitor and a tlr7 agonist
|
US10189846B2
(en)
|
2016-06-10 |
2019-01-29 |
Enanta Pharmaceuticals, Inc. |
Hepatitis B antiviral agents
|
JP7012668B2
(en)
|
2016-06-12 |
2022-02-14 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Dihydropyrimidinylbenzazepine dicarboxamide compound
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
BR112018076534A2
(en)
|
2016-06-20 |
2019-04-02 |
Incyte Corporation |
heterocyclic compounds as immunomodulators
|
WO2017219931A1
(en)
|
2016-06-22 |
2017-12-28 |
四川科伦博泰生物医药股份有限公司 |
Dihydro pteridinone derivative, preparation method therefor, and application thereof
|
JP6821716B2
(en)
|
2016-06-29 |
2021-01-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
A novel dihydropyrrolopyrimidine for the treatment and prevention of hepatitis B virus infection
|
JP6742452B2
(en)
|
2016-06-29 |
2020-08-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Novel tetrahydropyridopyrimidines for treatment and prevention of HBV infection
|
US10975077B2
(en)
|
2016-06-29 |
2021-04-13 |
Novira Therapeutics, Inc. |
Diazepinone derivatives and their use in the treatment of hepatitis B infections
|
US10071079B2
(en)
|
2016-06-29 |
2018-09-11 |
Bristol-Myers Squibb Company |
[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
|
CN109843892B
(en)
|
2016-06-29 |
2022-01-25 |
诺维拉治疗公司 |
Oxadiazepinone derivatives and their use in the treatment of hepatitis B infections
|
KR102468272B1
(en)
|
2016-06-30 |
2022-11-18 |
삼성전자주식회사 |
Acoustic output device and control method thereof
|
JP7171444B2
(en)
|
2016-07-01 |
2022-11-15 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
Dihydropyranopyrimidines for treating viral infections
|
EP3507367A4
(en)
|
2016-07-05 |
2020-03-25 |
Aduro BioTech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
CA3029991A1
(en)
|
2016-07-08 |
2018-01-11 |
Bristol-Myers Squibb Company |
1,3-dihydroxy-phenyl derivatives useful as immunomodulators
|
CN109476659B
(en)
|
2016-07-14 |
2021-07-09 |
豪夫迈·罗氏有限公司 |
Novel tetrahydropyrazolopyridine compounds for the treatment of infectious diseases
|
ES2930092T3
(en)
|
2016-07-14 |
2022-12-07 |
Incyte Corp |
Heterocyclic compounds as immunomodulators
|
WO2018011162A1
(en)
|
2016-07-14 |
2018-01-18 |
F. Hoffmann-La Roche Ag |
Carboxy 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
|
WO2018011160A1
(en)
|
2016-07-14 |
2018-01-18 |
F. Hoffmann-La Roche Ag |
6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
|
JP7051804B2
(en)
|
2016-07-14 |
2022-04-11 |
エフ.ホフマン-ラ ロシュ アーゲー |
6,7-dihydro-4H-pyrazolo [1,5-a] pyrazine compound and 6,7-dihydro-4H-triazolo [1,5-a] pyrazine compound for the treatment of infectious diseases
|
WO2018019297A1
(en)
|
2016-07-29 |
2018-02-01 |
银杏树药业(苏州)有限公司 |
Isoquinolinone compound and use thereof in preparation of antiviral drugs
|
CN110240596B
(en)
|
2016-07-29 |
2020-09-11 |
新波制药有限公司 |
Therapeutic agents for the treatment of HBV infection
|
EA038972B1
(en)
|
2016-07-30 |
2021-11-16 |
Бристол-Маерс Сквибб Компани |
Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
|
CA3030773A1
(en)
|
2016-08-03 |
2018-02-08 |
Arising International, Inc. |
Symmetric or semi-symmetric compounds useful as immunomodulators
|
MX2019001096A
(en)
|
2016-08-08 |
2019-07-04 |
Merck Patent Gmbh |
Tlr7/8 antagonists and uses thereof.
|
WO2018036941A1
(en)
|
2016-08-24 |
2018-03-01 |
F. Hoffmann-La Roche Ag |
Combination therapy of an hbv capsid assembly inhibitor and a nucleos(t)ide analogue
|
CA3034553A1
(en)
|
2016-08-26 |
2018-03-01 |
3M Innovative Properties Company |
Fused [1,2]imidazo[4,5-c] ring compounds substituted with guanidino groups
|
EP3504198B1
(en)
|
2016-08-29 |
2023-01-25 |
Incyte Corporation |
Heterocyclic compounds as immunomodulators
|
US10144706B2
(en)
|
2016-09-01 |
2018-12-04 |
Bristol-Myers Squibb Company |
Compounds useful as immunomodulators
|
EP3507276B1
(en)
|
2016-09-02 |
2021-11-03 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
US10640499B2
(en)
|
2016-09-02 |
2020-05-05 |
Gilead Sciences, Inc. |
Toll like receptor modulator compounds
|
WO2018043747A1
(en)
|
2016-09-05 |
2018-03-08 |
国立大学法人京都大学 |
Anti-hepatitis b virus agent
|
EP3510036B1
(en)
|
2016-09-07 |
2021-07-21 |
GlaxoSmithKline Biologicals SA |
Imidazoquinoline derivatives and their use in therapy
|
AU2017323584C1
(en)
|
2016-09-09 |
2020-09-17 |
Novartis Ag |
Compounds and compositions as inhibitors of endosomal toll-like receptors
|
CN109803967B
(en)
|
2016-09-09 |
2022-05-24 |
浙江海正药业股份有限公司 |
Dihydropyrimidine compound and preparation method and application thereof
|
KR102519535B1
(en)
|
2016-09-09 |
2023-04-06 |
브리스톨-마이어스 스큅 컴퍼니 |
Pyridyl substituted indole compounds
|
WO2018051254A1
(en)
|
2016-09-14 |
2018-03-22 |
Aurigene Discovery Technologies Limited |
Cyclic substituted-1,2,4-oxadiazole compounds as immunomodulators
|
WO2018051255A1
(en)
|
2016-09-14 |
2018-03-22 |
Aurigene Discovery Technologies Limited |
Cyclic substituted-1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
|
US10537590B2
(en)
|
2016-09-30 |
2020-01-21 |
Boehringer Ingelheim International Gmbh |
Cyclic dinucleotide compounds
|
AR109788A1
(en)
|
2016-10-04 |
2019-01-23 |
Merck Sharp & Dohme |
BENZO COMPOUNDS [B] THIOPHEN AS STING AGONISTS
|
WO2018065360A1
(en)
|
2016-10-07 |
2018-04-12 |
Biolog Life Science Institute Forschungslabor Und Biochemica-Vertrieb Gmbh |
Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways
|
DK3526323T3
(en)
|
2016-10-14 |
2023-06-26 |
Prec Biosciences Inc |
MODIFIED MEGANUCLEASES SPECIFIC FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME
|
US20200061030A1
(en)
|
2016-10-20 |
2020-02-27 |
Aurigene Discovery Technologies Limited |
Dual inhibitors of vista and pd-1 pathways
|
EP3532069A4
(en)
|
2016-10-26 |
2020-05-13 |
Merck Sharp & Dohme Corp. |
Antiviral aryl-amide phosphodiamide compounds
|
WO2018078149A1
(en)
|
2016-10-31 |
2018-05-03 |
F. Hoffmann-La Roche Ag |
Novel cyclicsulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
|
US10988507B2
(en)
|
2016-11-07 |
2021-04-27 |
Bristol-Myers Squibb Company |
Immunomodulators
|
JP6932394B2
(en)
|
2016-11-11 |
2021-09-08 |
ヘポ ファーマスーティカル カンパニー リミテッド |
Nitrogen-containing heterocyclic compounds, production methods, intermediates, pharmaceutical compositions and applications
|
US11370794B2
(en)
|
2016-11-11 |
2022-06-28 |
Dynavax Technologies Corporation |
Toll-like receptor antagonist compounds and methods of use
|
JOP20170188A1
(en)
|
2016-11-25 |
2019-01-30 |
Janssen Biotech Inc |
Cyclic dinucleotides as sting agonists
|
PT3546457T
(en)
|
2016-11-28 |
2021-08-06 |
Jiangsu Hengrui Medicine Co |
Pyrazolo-heteroaryl derivative, preparation method and medical use thereof
|
JOP20170192A1
(en)
|
2016-12-01 |
2019-01-30 |
Takeda Pharmaceuticals Co |
Cyclic dinucleotide
|
ES2891528T3
(en)
|
2016-12-20 |
2022-01-28 |
Bristol Myers Squibb Co |
Compounds useful as immunomodulators
|
RU2019122602A
(en)
|
2016-12-20 |
2021-01-22 |
Мерк Шарп И Доум Корп. |
COMBINATIONS OF PD-1 ANTAGONISTS AND CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT
|
RU2019122598A
(en)
|
2016-12-20 |
2021-01-22 |
Мерк Шарп И Доум Корп. |
CYCLIC DINUCLEOTIDE STING AGONISTS FOR CANCER TREATMENT
|
WO2018119263A1
(en)
|
2016-12-22 |
2018-06-28 |
Incyte Corporation |
Heterocyclic compounds derivatives as pd-l1 internalization inducers
|
BR112019013017A2
(en)
|
2016-12-22 |
2020-01-14 |
Idenix Pharmaceuticals Llc |
tenofovir antiviral aliphatic ester compounds or pharmaceutically acceptable salts thereof, pharmaceutical composition and use thereof
|
EP3558963B1
(en)
|
2016-12-22 |
2022-03-23 |
Incyte Corporation |
Bicyclic heteroaromatic compounds as immunomodulators
|
MA47120A
(en)
|
2016-12-22 |
2021-04-28 |
Incyte Corp |
PYRIDINE DERIVATIVES USED AS IMMUNOMODULATORS
|
CA3046029A1
(en)
|
2016-12-22 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antiviral benzyl-amine phosphodiamide compounds
|
EP3558985B1
(en)
|
2016-12-22 |
2022-09-07 |
Incyte Corporation |
Benzooxazole derivatives as immunomodulators
|
EP3558989B1
(en)
|
2016-12-22 |
2021-04-14 |
Incyte Corporation |
Triazolo[1,5-a]pyridine derivatives as immunomodulators
|
WO2018199338A1
(en)
|
2017-04-27 |
2018-11-01 |
国立大学法人広島大学 |
Nucleic acid molecule for treatment of hepatitis b
|
TW201945388A
(en)
|
2018-04-12 |
2019-12-01 |
美商精密生物科學公司 |
Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis B virus genome
|